Disease Progression Modeling: Key Concepts and Recent Developments
暂无分享,去创建一个
[1] Maurizio Fava,et al. Amyotrophic lateral sclerosis disease progression model , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[2] R. Gomeni,et al. Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. , 2007, British journal of clinical pharmacology.
[3] Karline Soetaert,et al. Solving Differential Equations in R: Package deSolve , 2010 .
[4] K. Peace,et al. The effect of tacrine and lecithin in Alzheimer's disease , 2004, European Journal of Clinical Pharmacology.
[5] D. Mould. Models for Disease Progression: New Approaches and Uses , 2012, Clinical pharmacology and therapeutics.
[6] Michael Krams,et al. Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder , 2009, Journal of Pharmacokinetics and Pharmacodynamics.
[7] Jan A M Raaijmakers,et al. Development of a Framework for Cohort Simulation in Cost-Effectiveness Analyses Using a Multistep Ordinary Differential Equation Solver Algorithm in R , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[8] J. Schellens,et al. Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin , 2015, CPT: pharmacometrics & systems pharmacology.
[9] C. Peck,et al. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model , 2000, Clinical pharmacology and therapeutics.
[10] V. Narayan,et al. Disease progression model for Clinical Dementia Rating–Sum of Boxes in mild cognitive impairment and Alzheimer’s subjects from the Alzheimer’s Disease Neuroimaging Initiative , 2014, Neuropsychiatric disease and treatment.
[11] Jon Neville,et al. Development of a unified clinical trial database for Alzheimer's disease , 2015, Alzheimer's & Dementia.
[12] Danny Chen,et al. An updated Alzheimer’s disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM , 2014, Journal of Pharmacokinetics and Pharmacodynamics.
[13] Jae Eun Ahn,et al. Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation , 2010, Journal of Pharmacokinetics and Pharmacodynamics.
[14] Hiroaki Kitano,et al. The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models , 2003, Bioinform..
[15] J. Nutt,et al. Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[16] A. Pestronk,et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. , 1991, Archives of neurology.
[17] J. Nutt,et al. Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. , 2012, British journal of clinical pharmacology.
[18] E. Gamazon,et al. Genome-wide interrogation of longitudinal FEV1 in children with asthma. , 2014, American journal of respiratory and critical care medicine.
[19] MC Peterson,et al. FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment? , 2015, CPT: pharmacometrics & systems pharmacology.
[20] Janet Woodcock,et al. The FDA critical path initiative and its influence on new drug development. , 2008, Annual review of medicine.
[21] K E Peace,et al. Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[22] F. Pichler,et al. INTERACTION INITIATIVES BETWEEN REGULATORY, HEALTH TECHNOLOGY ASSESSMENT AND COVERAGE BODIES, AND INDUSTRY , 2012, International Journal of Technology Assessment in Health Care.
[23] Joseph Beyene,et al. Longitudinal Data Analysis in Genome‐Wide Association Studies , 2014, Genetic epidemiology.
[24] D. Mould. Developing Models of Disease Progression , 2006 .
[25] Kaori Ito,et al. Disease progression meta-analysis model in Alzheimer's disease , 2010, Alzheimer's & Dementia.
[26] D Polhamus,et al. The future is now: Model‐based clinical trial design for Alzheimer's disease , 2015, Clinical pharmacology and therapeutics.
[27] K E Peace,et al. Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[28] J. Weuve,et al. 2016 Alzheimer's disease facts and figures , 2016 .
[29] Matthew M Riggs,et al. A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. , 2010, Bone.
[30] William J. Jusko,et al. Pharmacokinetic/Pharmacodynamic Modelling in Diabetes Mellitus , 2008, Clinical pharmacokinetics.
[31] M. Gibbs,et al. Model‐Based Meta‐Analysis for Comparative Efficacy and Safety: Application in Drug Development and Beyond , 2011, Clinical pharmacology and therapeutics.
[32] Lawrence J Lesko,et al. Quantitative disease, drug, and trial models. , 2009, Annual review of pharmacology and toxicology.
[33] Maciej J. Swat,et al. The impact of mathematical modeling on the understanding of diabetes and related complications , 2013, CPT: pharmacometrics & systems pharmacology.
[34] J. Schellens,et al. Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin , 2015, CPT: pharmacometrics & systems pharmacology.
[35] K. Davis,et al. A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.
[36] I. Lombardo,et al. The efficacy of RVT-101, a 5-ht6 receptor antagonist, as an adjunct to donepezil in adults with mild-to-moderate Alzheimer’s disease: Completer analysis of a phase 2b study , 2015, Alzheimer's & Dementia.
[37] B P Booth,et al. Elucidation of Relationship Between Tumor Size and Survival in Non‐Small‐Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development , 2009, Clinical pharmacology and therapeutics.
[38] Jan Fagerberg,et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Zheyang Wu,et al. Longitudinal Data Analysis for Genetic Studies in the Whole‐Genome Sequencing Era , 2014, Genetic epidemiology.
[40] Kaori Ito,et al. Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database , 2011, Alzheimer's & Dementia.
[41] L. Friberg,et al. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia , 2012, Cancer Chemotherapy and Pharmacology.
[42] Jon Neville,et al. Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database. , 2013, Journal of Alzheimer's disease : JAD.
[43] W Ewy,et al. Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.
[44] A semi-mechanistic model of bone mineral density and bone turnover based on a circular model of bone remodeling , 2015, Journal of Pharmacokinetics and Pharmacodynamics.
[45] N Franklin Adkinson,et al. Long-term effects of budesonide or nedocromil in children with asthma. , 2000, The New England journal of medicine.
[46] S. Potkin,et al. Placebo response trajectories in short-term and long-term antipsychotic trials in schizophrenia , 2011, Schizophrenia Research.
[47] D. Mould,et al. Disease Progress Models , 2007 .
[48] Melanie I. Stefan,et al. BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models , 2010, BMC Systems Biology.
[49] J. Tonascia,et al. Budesonide and nedocromil did not improve lung function in children with asthma The Childhood Asthma Management Program Research Group. Long›term effects of budesonide or nedocromil in children , 2001 .
[50] V. Lobanov,et al. An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative , 2012, Journal of clinical pharmacology.
[51] R. Barker,et al. Modelling the natural history of Huntington's disease progression , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[52] P. Mecocci,et al. Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 , 2014, Journal of internal medicine.
[53] M. Riggs,et al. Predicting Nonlinear Changes in Bone Mineral Density Over Time Using a Multiscale Systems Pharmacology Model , 2012, CPT: pharmacometrics & systems pharmacology.
[54] Karline Soetaert,et al. Inverse Modelling, Sensitivity and Monte Carlo Analysis in R Using Package FME , 2010 .
[55] J. Cedarbaum,et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.
[56] M. Hamilton,et al. Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.
[57] Innovation OR Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .
[58] S. Shechter,et al. State‐space size considerations for disease‐progression models , 2013, Statistics in medicine.
[59] P. Volberding,et al. Zidovudine response relationships in early human immunodeficiency virus infection , 1993, Clinical pharmacology and therapeutics.
[60] Klaus Romero,et al. Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis , 2012, Journal of Pharmacokinetics and Pharmacodynamics.
[61] S. Visser,et al. Implementation of Quantitative and Systems Pharmacology in Large Pharma , 2014, CPT: pharmacometrics & systems pharmacology.
[62] D. Mould,et al. Chapter 22 – Disease Progress Models , 2012 .